Nexalin Technology, a company specializing in innovative medical solutions, has reported positive results from a clinical study evaluating its Gen-2 tACS (transcranial alternating current stimulation) device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study, conducted at the University of California, San Diego, in collaboration with the United States Department of Veterans Affairs (VA) San Diego Healthcare System, as well as the Radiology, Psychiatry, and Neurosciences Departments of UC San Diego, highlights the potential of this technology to address a significant unmet need.
Mild traumatic brain injury is a major concern for veterans and the general public, often leading to physical, cognitive, emotional, and behavioral deficits. Effective treatments for post-concussive symptoms (PCS) have been limited, and the underlying pathophysiology is not fully understood. Symptoms of PCS frequently overlap with those of post-traumatic stress disorder (PTSD), complicating diagnosis and treatment. The clinical trial was a randomized, double-blind, placebo-controlled study conducted over an eight-week period. Twenty-four veteran patients with mTBI received twelve sessions of either active tACS or sham tACS over four consecutive weeks, followed by a four-week follow-up period to assess outcomes.
The positive results from this study are significant given the substantial market potential for treatments addressing traumatic brain injuries. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is projected to reach over $7.2 billion by 2032. Nexalin's innovative approach offers promise in addressing the needs of individuals suffering from mTBI, potentially improving their quality of life and providing hope for effective treatment options in the future.
For HR vendors and professionals in the talent management space, this news underscores the growing intersection of healthcare technology and workforce well-being. As employers increasingly focus on employee health and productivity, treatments that address mTBI—a condition prevalent among veterans and civilians alike—could have significant implications for workplace accommodations, disability management, and return-to-work programs. Companies that offer employee assistance programs or health benefits may need to consider emerging therapies like tACS as part of their holistic wellness offerings. Additionally, the projected market growth signals opportunities for vendors developing digital health solutions, training modules for managers on supporting employees with brain injuries, or analytics tools to track outcomes of such interventions.
Nexalin's study adds to the evidence base for non-invasive brain stimulation techniques, which could reshape how employers and HR departments approach cognitive health and pain management in the workplace. As the veteran population continues to integrate into the civilian workforce, innovations that alleviate the burden of mTBI could enhance retention and productivity, making this a development worth monitoring for HR technology vendors.
